During an interview with CNBC, Mike Doustdar discussed Novo Nordisk's strategy in light of increasing competition in the weight-loss sector. He emphasized the company's interest in identifying and acquiring firms that could offer superior drug options, particularly as investor sentiment remains cautious following a recent Capital Markets Day event.
At this event, Novo presented a turnaround plan that did not sufficiently reassure investors about its future competitiveness, especially with the impending loss of exclusivity for Wegovy. Following this announcement, Novo's stock experienced a decline, falling nearly 8% on Monday, marking its worst trading day since February.
Doustdar acknowledged the need for further efforts to convince investors of the company's strategic direction and diversification plans